Pravastatin

Chemical name

1,2,6,7,8,8а-Гексагидро-бе��а,дельта,6-тригидрокс��-2-метил-8-(2-метил-1-окс��бутокси)-1-нафталенге��тановая acid (and in the form of sodium salt)

Gross

C23-H36-O7

Characteristics

White or colourless cr 218 ystalline powder odourless. It is soluble in water, poorly soluble in isopropanol and virtually nerastvorim in acetone, acetonitrile and chloroform.

Of drugs

The drugs-gipolipidemicescoe. Ingibiruet Koa-reduktazu GMT, and suppresses the biosynthesis of the cholesterol in the liver, reduces vnutricletocny pool cholesterol, increases metabolism and klirens engineers and hampers education LPONP (predecessors claimed) in a Pecheni.pri inside absorbed to 54% (reception for 1 hour before or with meals reduc 218 es the systemic bioavailability and specific activity). Treated significantly linking gepatocitami after first passing "through the liver. C_max achieved through 1-1.5 hrs Associated with blood plasma proteins by 50%. Biotransformation is being addressed in several ways : Isomerization to 6-epiprawastatina and 3-gidroxiizomera, fermentativoe gidrauxilirovnie ring and the subsequent oxidation to ketone, air oxidation or carboxylic all circuits algae; Basic food metabolism - 3-gidroxiizomera possess specific activity on the order of 1 / 14 to 1 / 10 of the original. T_1/2 for prawastatina and its metabolites was 77 hours About 20% of the oral dose imposed excreted in the urine and 70% in feces, about 47% of the total Cl are in the kidneys and 53% in the ekstrarenale (ie biliary and биотрансформационный ). Because of the two ways to bring greater compensatornoe off on any one of them if 218 there is a violation of others, as well as the development of cumulation prawastatina and its metabolites in the human liver and / or kidney.

Indications

Giperlipidemia without disease (risk myocardial infarction), arteriosclerosis and ischemic heart disease, including myocardial infarction (to slow progression of atherosclerosis and reduce the likelihood of repeat heart attacks), giperlipidemia II type (increase of engineers, LPONP, total cholesterol), family giperholesterinemia (in patients with heart transplantirovannam to reduce the chance of developing coronary angiopatii).

Pregnancy and lactation

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Contraindications

Hypersensitivity, liver disease and / or breach of its responsibilities, pregnancy, breast-feeding, child, adolescent and youth age (up to 18 years).

Side-Effects

Дисфункция черепно-мозговых нервов (нарушение вкуса, непроизвольные движения глаз, парез лицевого нерва), тремор, головокружени� 218 �, тревога, бессонница, депрессия, амнезия, парестезии, периферические полинейропатии, панкреатит, гепатит (включая хронический активный и холестатический), жировая инфильтрация, цирроз или некроз печени, гепатома, анорексия, тошнота, миопатия, артралгия, острая почечная недостаточность на ф�